Ocrelizumab for progressive MS trail results

Genentech have announced positive results from a phase III study of ocrelizumab in primary progressive MS. The ORATORIO trial was looking for reductions in progression, as measured by EDSS, sustained for 12 weeks. Little detail in the press release, but top line results will be presented at the ECTRIMS conference in October. PharmiWeb Ocrelizumab - drugs in development
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news